Safety of Biological Therapy in Children With Inflammatory Bowel Disease

Conclusions: Our findings confirm a good safety profile of biologics. Infusion reactions to IFX administration remain one of the main issues, significantly linked to its immunogenicity and consequently with an impact on its efficacy and durability.
Source: Journal of Pediatric Gastroenterology and Nutrition - Category: Gastroenterology Tags: Original Articles: Gastroenterology: Inflammatory Bowel Disorders Source Type: research

Related Links:

Purpose of review This review aims to summarize the current evidence regarding the risks and implications of coronavirus disease 2019 (COVID-19) in patients with inflammatory bowel disease (IBD) and discuss optimal management of IBD during this pandemic. Recent findings Patients with IBD are not at increased risk of COVID-19 but several risk factors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 infection) have been identified, such as active IBD, obesity, and corticosteroid use. COVID-19 outcomes are similar among patients with IBD and the overall population. Although biologics have not been sh...
Source: Current Opinion in Gastroenterology - Category: Gastroenterology Tags: INFLAMMATORY BOWEL DISEASE: Edited by Miguel D. Regueiro Source Type: research
Biomed Pharmacother. 2021 May 28;140:111785. doi: 10.1016/j.biopha.2021.111785. Online ahead of print.ABSTRACTCoronavirus disease 2019 (COVID-19) has caused significant devastation globally. Despite the development of several vaccines, with uncertainty around global uptake and vaccine efficacy, the need for effective therapeutic agents remains. Increased levels of cytokines including tumour necrosis factor are significant in the pathogenesis of COVID-19 and associated with poor outcomes including ventilator requirement and mortality. Repurposing tumour necrosis factor blocker therapy used in conditions such as rheumatoid a...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Source Type: research
Early indicators suggest that highly effective messenger RNA (mRNA) vaccinations (BNT 162b2 [Pfizer-BioNTech] and mRNA-1273 [NIH-Moderna]) are beginning to curb the coronavirus disease 2019 (COVID-19) pandemic that has already taken the lives of 3 million individuals worldwide. However, questions about vaccine effectiveness remain for individuals with inflammatory bowel disease (IBD), including Crohn ’s disease and ulcerative colitis, who are frequently treated with immune suppression.1 An early study among transplant recipients indicated low humoral immune response after an initial vaccination, in contrast to the ro...
Source: Gastroenterology - Category: Gastroenterology Authors: Tags: Brief Communication Source Type: research
Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly expanded; however, clinical trials excluded patients taking immunosuppressive medications such as those with inflammatory bowel disease (IBD). Therefore, we explored real-world effectiveness of coronavirus disease 2019 (COVID-19) vaccination on subsequent infection in patients with IBD with diverse exposure to immunosuppressive medications.
Source: Gastroenterology - Category: Gastroenterology Authors: Tags: Clinical —Alimentary Tract Source Type: research
TUESDAY, May 18, 2021 -- Individuals with inflammatory bowel disease who are treated with infliximab rather than vedolizumab have reduced immunogenicity to a single dose of BNT162b2 and ChAdOx1 nCoV-19 severe acute respiratory syndrome coronavirus 2...
Source: - Pharma News - Category: Pharmaceuticals Source Type: news
Inflammatory bowel disease (IBD) patients with Crohn ’s disease and ulcerative colitis have been considered at increased risk of severe coronavirus disease 2019 (COVID-19) because they are often treated with immunosuppressive medications. Indeed, steroids and thiopurines in combination therapy with tumor necrosis factor (TNF) antagonists, but not TN F antagonist monotherapy, have been associated with a risk of severe COVID-19 in IBD patients.1,2 Expert consensus advocates that IBD patients should be vaccinated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Source: Gastroenterology - Category: Gastroenterology Authors: Tags: Brief Communication Source Type: research
AbstractGastrointestinal diseases such as celiac disease, functional gastrointestinal disorders (FGIDs), inflammatory bowel disease (IBDs) and acute or chronic diarrhea are quite frequent in the pediatric population. The approach, the diagnosis and management can be changed in the 2019 coronavirus disease (COVID-19) pandemic era. This review has focused on: i) the current understanding of digestive involvement in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected children and adolescents and the clinical implications of COVID-19 for pediatric gastroenterologists, ii) the impact of COVID-19 on the clinica...
Source: Italian Journal of Pediatrics - Category: Pediatrics Source Type: research
As summer turns to fall, clinicians' minds usually turn to the upcoming winter season and preparing for winter infections, particularly influenza. In 2020, though, we face a new and formidable foe: the severe acute respiratory syndrome novel coronavirus-2 (SARS-CoV-2). Although we hope that an effective vaccine against SARS-CoV-2 will soon be available, the distribution of an effective vaccine is not likely to occur soon, so it is especially appropriate to use the other tools already at our disposal to keep our patients with inflammatory bowel disease (IBD) well.
Source: Gastroenterology - Category: Gastroenterology Authors: Tags: Commentary Source Type: research
Authors: Konturek PC, Harsch IA, Neurath MF, Zopf Y Abstract Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV2) outbreak is the most dramatic event since World War II. Originating as a cluster of unexplained cases of pneumonia, it turned out that this viral disease termed COVID-19 is not only a respiratory infection, but a systemic disease associated with a number of extrapulmonary complications. One of the medical disciplines that is strongly affected by this viral infection is gastroenterology. COVID-19 causes in some patients typical symptoms of enteritis such as diarrhea or abdominal pain. There is als...
Source: Journal of Physiology and Pharmacology - Category: Drugs & Pharmacology Tags: J Physiol Pharmacol Source Type: research
The objective is to start treating chronic diseases from the root and not the symptoms of the disease. As we are starting to enroll patients in "senolytics-clinical trials," it will be imperative to assess if senolysis efficiently targets the primary cause of disease or if it works best in combination with other drugs. Additional basic science research is required to address the fundamental role of senescent cells, especially in the established contexts of disease. Notes on Self-Experimentation with Sex Steroid Ablation for Regrowth of the Thymus
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
More News: Children | Coronavirus | COVID-19 | Gastroenterology | Humira | Inflammatory Bowel Disease | Nutrition | Pediatrics | Remicade | Stelara | Study | Vaccines